Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immun...
February 27 2017 - 08:00AM
Business Wire
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical
company developing CODIT™ (Characterized Oral
Desensitization ImmunoTherapy) treatments for
life-threatening food allergies, today announced that new clinical
data on AR101 will be presented during poster sessions on Monday,
March 6, at the 2017 American Academy of Allergy, Asthma &
Immunology (AAAAI) Annual Meeting taking place March 3–6, 2017, in
Atlanta, Georgia. The presentations will report data from the Phase
2 ARC001 study (Abstract 803) and from the screening population of
the PALISADE Phase 3 study (Abstracts L20 and 807). Presentation
details are as follows:
Abstract 803: Jones S, et al., At-home dosing adherence
during characterized oral desensitization immunotherapy (CODIT) for
peanut allergy; Poster Session #4210 on Allergen Extracts and Other
Forms of Immunotherapy, 9:45 AM – 10:45 AM Eastern Time, Monday,
March 6, 2017, in Building B, Level 1, Exhibit Hall B2. The
abstract may be viewed online at
http://www.jacionline.org/article/S0091-6749(16)32342-9/pdf.
Abstract L20: Vickery BP, et al., Outcome of 583 entry
double-blind placebo-controlled peanut challenges during screening
for the PALISADE Phase 3 oral immunotherapy trial; Late Breaking
Poster Session #4213, 9:45 AM - 10:45 AM Eastern Time, Monday,
March 6, 2017, in Building B, Level 1, Exhibit Hall B2. The
abstract may be viewed online at
http://www.jacionline.org/article/S0091-6749(16)32432-0/pdf.
Abstract 807: Rust B, et al., Dual assessment of
peanut-specific effector and regulatory T cells in patients
undergoing oral immunotherapy; Poster Session #4210 on Allergen
Extracts and Other Forms of Immunotherapy, 9:45 AM – 10:45 AM
Eastern Time, Monday, March 6, 2017, in Building B, Level 1,
Exhibit Hall B2. The abstract may be viewed online at
http://www.jacionline.org/article/S0091-6749(16)32346-6/pdf.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage
biopharmaceutical company developing treatments for
life-threatening food allergies. The company’s Characterized
Oral Desensitization ImmunoTherapy
(CODIT™) approach is intended to achieve meaningful levels of
protection by desensitizing patients with defined, precise amounts
of key allergens. Aimmune’s first investigational product using
CODIT™, AR101 for the treatment of peanut allergy, has received the
FDA’s Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4-17 years of age and is currently being
evaluated in Phase 3 clinical trials in ages 4-55. AR101 is a
characterized, regulated, oral biological drug product containing
the protein profile found in peanuts. For more information, please
see www.aimmune.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170227005327/en/
Aimmune Therapeutics, IncInvestorsLaura Hansen, Ph.D.,
650-396-3814lhansen@aimmune.comorMediaStephanie Yao,
650-351-6479syao@aimmune.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Mar 2023 to Mar 2024